Tamoxifen, an estrogen receptor alpha (ERα) antagonist, was first introduced as a palliative agent for advanced breast cancer during the 1970s, but was later proven to be an effective adjuvant therapy for ERα-positive breast cancer patients13. The gene discussed is ESR1; the disease is breast carcinoma.